Measurement of increases in anti‐double‐stranded dna antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus
- 1 May 1990
- journal article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 33 (5), 634-643
- https://doi.org/10.1002/art.1780330505
Abstract
To evaluate the predictive power of changes in levels of antibodies to double‐stranded DNA (anti‐dsDNA) as a predictor of disease exacerbations in systemic lupus erythematosus (SLE), we performed a prospective study on 72 unselected patients with SLE (mean duration of study 18.5 months, range 6–35 months). Patients were seen at least once every 3 months, and disease activity was scored according to a specific protocol. Plasma samples were obtained at least once every month and were assessed for anti‐dsDNA antibody (by the Crithidia luciliae assay, an enzymelinked immunosorbent assay [ELISA], and the Farr assay) and for complement components C3 and C4. Twenty‐seven of 33 disease exacerbations observed during the study period were accompanied by a positive test result for anti‐dsDNA antibody (27 by the Farr assay, 19 by the C luciliae assay, and 23 by the ELISA). Twenty‐four of these exacerbations were preceded by a significant increase in anti‐dsDNA antibody levels (23 by the Farr assay, 12 by the C luciliae assay, and 17 by the ELISA). The first observance of a significant increase in anti‐dsDNA antibody levels preceded the exacerbation by 8–10 weeks. Significant increases in anti‐dsDNA antibody levels not followed by an exacerbation were observed in 5 cases by the Farr assay, in 7 cases by the C luciliae assay, and in 3 cases by the ELISA; however, in 3 cases, 2 cases, and 1 case, respectively, these increases were followed by an increase in disease activity that did not fulfill the criteria for an exacerbation. Serial measurement of anti‐dsDNA antibody levels was more sensitive for predicting exacerbations than was measurement of C3 and/or C4 levels (P < 0.03). Serial assessment of anti‐dsDNA antibody levels, especially by the Farr assay, is a sensitive and reasonably specific method for predicting disease exacerbations in SLE.Keywords
This publication has 31 references indexed in Scilit:
- Specificity of anti-Sm antibodies by ELISA for systemic lupus erythematosus: increased sensitivity of detection using purified peptide antigens.Annals Of The Rheumatic Diseases, 1988
- The first international standard for antibodies to double stranded DNA.Annals Of The Rheumatic Diseases, 1988
- Disease activity in systemic lupus erythematosus related to a range of antibodies binding DNA and synthetic polynucleotides.Annals Of The Rheumatic Diseases, 1988
- Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus.Annals Of The Rheumatic Diseases, 1986
- Complement fixation by anti-dsDNA antibodies in SLE: measurement by radioimmunoassay and relationship with disease activity.Annals Of The Rheumatic Diseases, 1986
- A longitudinal study of high and low avidity antibodies to double‐stranded DNA in systemic lupus erythematosusArthritis & Rheumatism, 1985
- Correlation between levels of DNA antibodies and clinical disease activity in SLE.Annals Of The Rheumatic Diseases, 1977
- Prognostic significance of DNA-binding capacity patterns in patients with lupus nephritis.Annals Of The Rheumatic Diseases, 1975
- Free DNA in serum and plasma from normal adults.JCI Insight, 1975
- Longitudinal Studies of Anti-Dna Antibody Levels in SleScandinavian Journal of Rheumatology, 1975